In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The positive result of late potential after percutaneous coronary intervention for acute coronary syndromes may help the evaluation of the cardiovascular events.

Session Poster session 6

Speaker Associate Professor Mari Amino

Congress : ESC Congress 2017

  • Topic : arrhythmias and device therapy
  • Sub-topic : Arrhythmias, General - Diagnostic Methods
  • Session type : Poster Session
  • FP Number : P5528

Authors : M Amino (Isehara,JP), K Yoshioka (Isehara,JP), T Ichikawa (Toyoake,JP), E Watanabe (Toyoake,JP), M Nakamura (Isehara,JP), T Hashida (Isehara,JP), S Kanda (Isehara,JP), Y Ikari (Isehara,JP)

Authors:
M. Amino1 , K. Yoshioka1 , T. Ichikawa2 , E. Watanabe2 , M. Nakamura1 , T. Hashida1 , S. Kanda1 , Y. Ikari1 , 1Tokai University School of Medicine - Isehara - Japan , 2Fujita Health University School of Medicine, Department of Cardiology - Toyoake - Japan ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 1183

Background: It is known that >60,000 people die of sudden cardiac death every year in japan. Among them, about 80% are caused by lifethreatening ventricular arrhythmias and a greater part of them based on ischemic cardiac disease.

Objective: The aim of this study was to investigate the significance of late potential (LP) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS).

Method: We enrolled 220 consecutive patients (177 male, 65±12.1 y/o) with ACS admitted to our University Hospital from January to December 2012. Twenty-four hour high-resolution ambulatory electrocardiogram was performed between post-PCI procedure and hospital discharge (8±0.5 days)). The 214 analyzable patients were divided into the LP-positive (n=43) and LP-negative (n=171) groups, and the relationship between LP and major adverse cardiovascular events (MACE; cardiogenic death, myocardial infarction [MI], re-hospitalization for unstable angina and chronic heart failure) was prospectively investigated. Patient's backgrounds were investigated as below; age, gender, coronary risk of hypertension / dyslipidemia / diabetes, past history of old MI and arrhythmia, additional medicine, brain natriuretic peptide and creatine phosphokinase on arrival, ejection fraction, culprit lesion, reperfusion time, and hospital days, creatinine and glomerular filtration rate.

Results: There were no significance of patient's background in 14 variables except serum creatinine and glomerular filtration rate (GFR) on arrival. Proportion of MACE was 30.2% in the LP-positive group and 11.7% in the LP-negative group (p<0.01; by the Chi square test), and different between groups by the Kaplan-Maier analysis (p=0.01; 572±40.6 days). In the multivariable analysis with following variables (ejection fraction, creatine phosphokinase, creatinine and GFR), the odds ratio of positive LP for MACE was 3.3 (95% confidence interval, 1.4–7.6; p<0.01).

Conclusion: Assessment of LP in ACS patients with PCI treatment may useful to predict the possible occurrence of MACE.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are